vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $53.00.

VTVT has been the subject of several research analyst reports. Evercore initiated coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target for the company. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th.

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock opened at $35.08 on Monday. The firm has a fifty day moving average of $33.93 and a two-hundred day moving average of $35.63. The stock has a market capitalization of $138.22 million, a price-to-earnings ratio of -37.72 and a beta of 0.27. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to the consensus estimate of $20.00 million. As a group, research analysts forecast that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the 4th quarter worth $221,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. 683 Capital Management LLC acquired a new position in vTv Therapeutics in the 4th quarter worth $731,000. Finally, Baker BROS. Advisors LP boosted its stake in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the period. 17.51% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.